Prolonged treatment of tumour cells with an anti-cancer drug may cause them to become resistant to a variety of drugs which differ in their mechanism of action, but share the property of entering the cells by passive diffusion through the membrane (Gerlach et al., 1986;  Stark, 1986; Gottesman & Pastan, 1988) . This multidrug resistance (MDR) has been closely linked to the specific amplification of expression of a particular class of transmembrane glycoprotein called the P-glycoprotein (Pgp) (Ling & Thompson, 1974; Bech-Hansen et al., 1975; Kartner et al., 1983; Ueda et al., 1987) . The P-glycoproteins decrease the intracellular concentration of the anti-cancer drug below its cytostatic threshold by actively pumping it out of the cell.
Various membrane active agents (calcium antagonists, local anaesthetics) or compounds reducing intracellular ATP levels have been shown to interfere with the Pgp function.
The immunosuppressive drug cyclosporin A (CsA, Sandimmune) has already been shown to reverse MDR. CsA corrects the daunorubicin resistance in Ehrlich ascites carcinoma (Slater et al., 1986a) and the daunorubicin and vincristine resistance in acute lymphatic leukaemia (Slater et al., 1986b) . CsA also enhances the daunorubicin efficacy in murine hepatoma (Meador et al., 1987) , modifies adriamycin and vincristine resistance in a MDR human lung cancer cell line (Twentyman et al., 1987) , and enhances the cytotoxicity of etoposide and adriamycin in L1210 leukaemic cells (Osieka et al., 1986) .
Two properties of CsA limit its use as a resistance modifying agent in cancer chemotherapy. They are the immunosuppressive potency of the drug and its clinical side-effects, especially nephrotoxicity, neither of which would be accep- (Ling & Thompson, 1974 , Bech-Hansen et al., 1975 . These cell lines were grown in culture medium (oxMEM medium supplemented with Asn 0.02 mg ml-', vitamins (1 x), penicillinstreptomycin 100 IU ml', Gln 2 mM and 10% heat inactivated fetal calf serum (all from Gibco)). Colchicine (Sandoz), daunomycin (Sigma D-4885), puromycin (Sigma P-7255), vincristine (Serva 38215) and gramicidin D (Serva 24150) were prepared as stock solutions in culture medium.
Immunosuppression
The degree of immunosuppressive activity of the different Cs derivatives had been previously assessed in several in vitro and in vivo models (Hiestand & Gubler, 1988) .
Proliferation assay of CHO cell lines
In preliminary experiments, we measured cell growth by methods such as 3H-thymidine uptake or a colorimetric assay (cell mass measurement by hexosaminidase content) (Koponen et al., 1982) , but another colorimetric assay using MTT (Mosmann, 1983) was found to be the most convenient for screening large numbers of derivatives. This assay had also been found very 'feasible' for drug screening with panels of tumour cell lines (Alley et al., 1988 The Cs derivatives to be tested were dissolved at 1 mg ml1l in absolute ethanol (EtOH, Merck) and were tested at 1 jig ml-', with control being treated with the corresponding ethanol solvent dilutions. The cyclosporin derivatives or control solutions were added (50 jl) to each well, and mixed the 100 ILI cell suspensions (4 x 103 cells ml-' for the parental line and 8 x 103 cells ml-' for the MDR line) and colchicine solutions (50 jl) which had been added beforehand.
After a 6-day incubation at 37°C, the final cell number was measured by a colorimetric assay using MTT (3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma) (Mosmann, 1983) . First, 100 jl of supernatant were removed, and then to the remaining cell suspension, 10 IL of the MTT solution (5 mg ml-') were added per well and the plates incubated for 3 h at 37°C; 100 tLI of solvent (butanol-2, isopropanol, HCI 1 N in volume ratio 16/8/1) were added per well and the plates shaken until complete dissolution of the formazan crystals. The OD was read at 540 nm on a plate reader (Titertek Multiskan). The extent of cell growth was represented as a function of the anti-cancer drug concentration (the growth in the absence of anti-cancer drug (Cs or solvent alone) being taken as 100%).
Data analysis
The anti-cancer drug IC50s were determined from the concentration-response curves: either in the presence of Cs (IC50 + ), or in its absence (IC50 -) (but in the presence of the Cs solvent, i.e. ethanol).
The increases of anti-cancer drug sensitivity or 'gain of sensitivity' brought by each Cs at 1 jig ml-' were given by the ratio IC50 -/C50 +. These measurements were performed for both cell lines (parental and MDR), for the various anti-cancer drugs assayed, and for 1 g ml-' Cs.
Results
In our assay system, we studied the effects of CsA and some of its derivatives at a concentration of 1 jLg ml-'. Indeed, maximum tolerable plasma levels of CsA are in the order of 1-2jgml-' (Kahan et al., 1983) . Moreover, none of the Cs derivatives reported in this paper was toxic by itself at 1 jLg ml-' on parental or MDR CHO cells, no detectable effect on their growth being detected up to 3 jig ml-' for all of them, and up to 10jigml-for most of them.
Effect of CsA, CsH and N-phenylaminothio-carbamoyl-CsA in combination with the anti-tumour drugs on the growth of parental and MDR lines The parental and MDR cell lines were first compared for sensitivity to colchicine, daunomycin and vincristine, and the IC50 (as jLg ml-') was determined for each drug. Colchicine, daunomycin and vincristine inhibited the cell growth at comparable concentrations ( Figure 1 , open and filled circles, for parental and MDR cells respectively). Gramicidin D and puromycin required high doses to inhibit the MDR line (IC50s>50 jg ml-', not shown). Figure 1 shows the effect of CsA, CsH and N-phenylaminothio-carbamoyl-CsA on the drug resistance of both CHO cell lines (the control growth in the absence of anti-tumour drug being considered as 100%), the dose-response curves being established with colchicine, vincristine and daunomycin. For the potentation of all three anti-cancer drugs (gains of sensitivity), CsA was the most active: the vincristine IC50 and daunomycin IC50 of MDR cells in the presence of CsA even fell below the vincristine IC50 and daunomycin IC50 of parental line in the absence of CsA. CsA was also effective on the parental line itself, the parental gains and MDR gains being respectively 10 and 14 for colchicine, 11 and 47 for daunomycin, and 22 and 77 for vincristine. The N-phenylaminothio-carbamoyl-CsA was essentially inactive, the gains of sensitivity being below 2. CsH, an immunologically inactive derivative of CsA, was weakly active in our assay, giving parental gains and MDR gains of, respectively, 4 and 2.5 for daunomycin, 4.5 and 2 for vincristine, and 6 and 1.2 for colchicine.
Effect of some Cs derivatives on resistance to colchicine, vincristine and daunomycin The IC50 ranges for colchicine, vincristine and daunomycin in our assay were the following, respectively (in ng ml-): 18.5-53, 50-175 and 14-23.5 for parental line, and 980-3,100, 660-5,900 and 500-2,100 for the MDR line.
The ability of some Cs derivatives with different immunosuppressive powers to sensitise parental and MDR CHO cells to the three anti-tumour drugs is shown in Table I for colchicine, in Table II for vincristine and in Table III 195 (148) 2175 (353) (Me-Ile'l)-Cs, (O-tBu-Ser8)-Cs, (3'desoxy-3'-oxo-MeBmt')-Cs, (Pro)3-Cs, (O-acetyl-Thr2)-Cs), and some were nonimmunosuppressive and inactive in MDR (CsH, N-phenylaminothio-carbamoyl-IsoCsA). All these Cs derivatives showed little activity on MDR cells at lower concentration (0.1 Ig ml', data not shown).
Some Cs of both the immunosuppressive category (CsG, (Me-Ala6)-Cs) and the non-immunosuppressive category ((OtBu-Ser8)-Cs, (Me-Ile")-Cs, (3'deoxy-3'oxo-MeBmt')-Cs)
were more active than CsA in MDR neutralisation.
Irrespective of the high gains of sensitivity obtained with MDR cells, the highest gain measured for parental cells was 17, which seems to be the maximum gain achievable. This corresponds to respective IC_0s for colchicine, vincristine and daunomycin of 2-3ngml [', 4-6ngml-' and 3-4ng-ml[', in the presence of the Cs derivatives. In the case of MDR cells, even a gain of 100, in the presence of the Cs derivative, corresponds to an IC5o for colchicine or daunomycin of about 20 ng ml-'.
Discussion
The use of cyclosporin A to overcome multidrug resistance of tumour cells has been reported by several investigators. Slater et al. (1986b) described some effect of CsA at 3.3 tg ml-' on vincristine and daunorubicin susceptibility of MDR acute lymphatic leukaemia cells but not of parental cells, whereas little effect was found for daunorubicin susceptibility of parental and MDR Ehrlich ascites carcinoma cells (about a 2-fold increase in sensitivity) (Slater et al., 1986a) . Meador et al. (1987) found some effect of CsA at 1 ,tg ml-' in drug sensitive Ehrlich ascites carcinoma and murine hepatoma 129 cell lines, although this effect was small compared to our experiments. Twentyman et al. (1987) (Inaba & Maruyama, 1988) and with the calcium channel blocker Verapamil (Beck et al., 1986 ).
The non-immunosuppressive cyclosporin, CsH, was inactive at 1 .g ml-' in reversing colchicine and vincristine resis- O-Acetyl-CsA>(Me-Ile")-Cs>CsA>(Me-Ala6)-Cs. In our hands, and considering only non-immunosuppressive Cs derivatives, (Me-Ile")-Cs and 0-acetyl-CsA gave the highest chemosensitisation to daunomycin whereas (0-tBu-Ser8)-Cs and (Me-Ile")-Cs gave the highest chemosensitisation to vincristine, and finally (0-tBu-Ser8)-Cs and (3'-deoxy-3'-oxoMeBmt')-Cs gave the highest chemosensitisation to colchicine. From our results and those of Twentyman (1988) , it thus appears that a given Cs derivative which may be the best to overcome resistance to one anti-tumour drug is not necessarily as effective in overcoming the resistance to several anti-tumour agents. Since immunosuppressive Cs derivatives bind to the 'intracellular receptor' cyclophilin, whereas non-immunosuppressive Cs do not (Handschumacher et al., 1984; Quesniaux et al., 1987 ), cyclophilin appears not to be involved in MDR. Naito and Tsuruo (1989) have demonstrated that CsA was as effective as vinblastine for the inhibition of the high affinity binding of vincristine to plasma membranes of MDR K562 cells. Whether the MDR active and inactive Cs actually decrease the anti-tumour drug efflux out of the cell and bind to the Pgp might help to elucidate the mechanism of action of Cs in MDR. Patients who require immunosuppression for organ transplantation or autoimmunity treatment might benefit from being treated with Cs derivatives which do not affect the function of their normal Pgp. In this regard, it is important that some We are very grateful to Dr Jean Borel who drew our attention to this new property of cyclosporin.
